Juliana Qin

Ms. Juliana Qin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Cell
Verified
Journal Article
Closed access
ISIan Setliff
Ian Setliff
ASAndrea R. Shiakolas
Andrea R. Shiakolas
KPKelsey A. Pilewski
Kelsey A. Pilewski
AMAmyn A. Murji
Amyn A. Murji
RMRutendo E. Mapengo
Rutendo E. Mapengo
IGIvelin Georgiev
Ivelin Georgiev

21 September 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MPMark M. Painter
Mark M. Painter
TJTimothy S. Johnston
Timothy S. Johnston
KLKendall A. Lundgreen
Kendall A. Lundgreen
JSJefferson Santos
Jefferson Santos
JQJuliana Qin
Juliana Qin
EWE. John Wherry
E. John Wherry

2 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
AMAmyn A. Murji
Amyn A. Murji
JQJuliana Qin
Juliana Qin
THTandile Hermanus
Tandile Hermanus
LMLynn Morris
Lynn Morris
IGIvelin Georgiev
Ivelin Georgiev
A leading strategy for developing a prophylactic HIV-1 vaccine is the elicitation of antibodies that can neutralize a large fraction of circulating HIV-1 variants. However, a major challenge that has limited the effectiveness of current vaccine candidates is the extensive global diversity of the HIV-1 envelope protein (Env), the sole target for HIV-neutralizing antibodies. To address this challenge, various strategies incorporating Env diversity into the vaccine formulation have been proposed. Here, we assessed the potential of two such strategies that utilize a nanoparticle-based vaccine platform to elicit broadly neutralizing antibody responses. The nanoparticle immunogens developed here consisted of different formulations of Envs from strains BG505 (clade A) and CZA97 (clade C), attached to the N-termini of bacterial ferritin. Single—antigen nanoparticle cocktails, as well as mosaic nanoparticles bearing both Env trimers, elicited high antibody titers in mice and guinea pigs. Furthermore, serum from guinea pigs immunized with nanoparticle immunogens achieved autologous, and in some cases heterologous, tier 2 neutralization, although significant differences between mosaic and single—antigen nanoparticles were not observed. These results provide insights into the ability of different vaccine strategies for incorporating Env sequence diversity to elicit neutralizing antibodies, with implications for the development of broadly protective HIV-1 vaccines.

3 December 2021 in iScience
Verified
Journal Article
Open access
AMAmyn A. Murji
Amyn A. Murji
NRNagarajan Raju
Nagarajan Raju
JQJuliana Qin
Juliana Qin
HKHaajira Kaldine
Haajira Kaldine
KJKatarzyna Janowska
Katarzyna Janowska
IGIvelin Georgiev
Ivelin Georgiev
Public antibody clonotypes shared among multiple individuals have been identified for several pathogens. However, little is known about the determinants of antibody “publicness”. Here, we characterize the sequence and functional properties of antibodies from a public clonotype targeting the CD4 binding site on HIV-1 Env. Our results showed that HIV-1 specificity for the public antibodies studied here, comprising sequences from three individuals, was modulated by the VH, but not VL, germline gene. Non-native pairing of public heavy and light chains from different individuals suggested functional complementation of sequences within this public antibody clonotype. The strength of antigen recognition appeared to be dependent on the specific antibody light chain used, but not on other sequence features such as native-antibody or germline sequence identity. Understanding the determinants of antibody clonotype “publicness” can provide insights into the fundamental rules of host-pathogen interactions at the population level, with implications for clonotype-specific vaccine development.